BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21126755)

  • 1. Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma.
    Obermair A; Mileshkin L; Bolz K; Kondalsamy-Chennakesavan S; Cheuk R; Vasey P; Wyld D; Goh J; Nicklin JL; Perrin LC; Sykes P; Janda M
    Gynecol Oncol; 2011 Feb; 120(2):179-84. PubMed ID: 21126755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
    Fields AL; Einstein MH; Novetsky AP; Gebb J; Goldberg GL
    Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma.
    Low JS; Wong EH; Tan HS; Yap SP; Chua EJ; Sethi VK; Soh LT; Low J; Tay EH; Chew SH
    Gynecol Oncol; 2005 Apr; 97(1):171-7. PubMed ID: 15790454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
    Dietrich CS; Modesitt SC; DePriest PD; Ueland FR; Wilder J; Reedy MB; Pavlik EJ; Kryscio R; Cibull M; Giesler J; Manahan K; Huh W; Cohn D; Powell M; Slomovitz B; Higgins RV; Merritt W; Hunter J; Puls L; Gehrig P; van Nagell JR
    Gynecol Oncol; 2005 Dec; 99(3):557-63. PubMed ID: 16154185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin.
    Le TD; Yamada SD; Rutgers JL; DiSaia PJ
    Gynecol Oncol; 1999 Jun; 73(3):461-3. PubMed ID: 10366480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of chemotherapy and radiation in uterine papillary serous carcinoma.
    Viswanathan AN; Macklin EA; Berkowitz R; Matulonis U
    Gynecol Oncol; 2011 Dec; 123(3):542-7. PubMed ID: 21963091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
    Fader AN; Nagel C; Axtell AE; Zanotti KM; Kelley JL; Moore KN; Secord AA; Walsh CS; Huh WK; Gehrig PA; Gibbons H; Rose PG; Havrilesky LJ; Tuller E; Drake RD; Bottsford-Miller J; O'Malley DM;
    Gynecol Oncol; 2009 Mar; 112(3):558-62. PubMed ID: 19118888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.
    Mahdi H; Elshaikh MA; DeBenardo R; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; Moslemi-Kebria M
    Gynecol Oncol; 2015 May; 137(2):239-44. PubMed ID: 25641568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
    Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; VillĂ  S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
    Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma.
    Einstein MH; Frimer M; Kuo DY; Reimers LL; Mehta K; Mutyala S; Huang GS; Hou JY; Goldberg GL
    Gynecol Oncol; 2012 Jan; 124(1):21-5. PubMed ID: 22035806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy in uterine papillary serous carcinoma.
    Resnik E; Taxy JB
    Gynecol Oncol; 1996 Jul; 62(1):123-7. PubMed ID: 8690284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.
    Thomas MB; Mariani A; Cliby WA; Keeney GA; Podratz KC; Dowdy SC
    Gynecol Oncol; 2007 Nov; 107(2):186-9. PubMed ID: 17688926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
    Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
    Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
    Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
    Gynecol Oncol; 1999 Aug; 74(2):272-7. PubMed ID: 10419744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Pelvic Radiation "Sandwiched" Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial.
    Frimer M; Miller EM; Shankar V; Girda E; Mehta K; Smith HO; Kuo DYS; Goldberg GL; Einstein MH
    Int J Gynecol Cancer; 2018 Nov; 28(9):1781-1788. PubMed ID: 30371562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.
    Hamilton CA; Cheung MK; Osann K; Balzer B; Berman ML; Husain A; Teng NN; Kapp DS; Chan JK
    Gynecol Oncol; 2006 Nov; 103(2):679-83. PubMed ID: 16793126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma.
    Hamilton CA; Liou WS; Osann K; Berman ML; Husain A; Teng NN; Kapp DS; Chan JK
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):839-44. PubMed ID: 16199314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
    Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
    Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
    Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
    Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
    Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.